Rhode Island is currently home to 495 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
NCT06316830
Recruiting
The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment respo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Opioid Use Disorder
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Early Alzheimer's Disease
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Rhode Island Hospital Hemostasis and Thrombosis Center, Providence, Rhode Island
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
NCT06849869
Recruiting
The collaborative care model (CCM) is a health services intervention that integrates mental health care in primary care settings. The goal of this study is to adapt the CCM to the perinatal care context, including community co-designed adaptations to enhance health equity (COMPASS+). The main objectives of the study are to: 1. Evaluate the effect of COMPASS+ on depression symptom outcomes. Specifically we will evaluate population-level depression symptom trajectories and the prevalence of suici... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Women and Infants Hospital, Providence, Rhode Island
Conditions: Perinatal Mental Health
Register for Updates
Choosing Wisely: De-implementing Fall Prevention Alarms in Hospitals
NCT06089239
Recruiting
This is a Hybrid II de-implementation study to reduce use of fall prevention alarms in hospitals. The intervention consists of tailored, site-specific approaches for three core implementation strategies: education, audit/feedback and opinion leaders. Hospital units will be randomized to low-intensity or high-intensity coaching for the implementation of the tailored strategies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Kent Hospital, Warwick, Rhode Island
Conditions: Accidental Fall, Patient Safety, Hospital Acquired Condition, Clinical Alarms, Mentoring
Register for Updates
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164
Recruiting
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Women & Infants Hospital of Rhode Island, Providence, Rhode Island
Conditions: Urgency Urinary Incontinence
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/24/2025
Locations: Research Site, Providence, Rhode Island
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Velocity Clinical Research - Providence- Site Number : 8401179, East Greenwich, Rhode Island
Conditions: Dermatitis Atopic
Register for Updates
Improving Social Connectedness Through Digital Health to Enhance Recovery from OUD Among the Justice Involved Population
NCT06896656
Recruiting
People with a history of Opioid Use Disorder and criminal justice involvement are more likely to experience loneliness following release from jail/prison leading to negative outcomes such as treatment dropout and increased substance use. Providing peer recovery support, particularly through a highly accessible, digital health platform, is a potential way to decrease loneliness in this population. The current study seeks to test whether a mobile peer recovery support app, delivered to individuals... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Loneliness, Opioid Use Disorder
Register for Updates
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
NCT05839119
Recruiting
This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy). In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the testos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Urothelial Carcinoma Bladder, Androgen Receptor Positive
Register for Updates
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab for Patients Who Are Disease Free After Completion of Trimodality Treatment for HER-2+ Cancers of Esophagus & Gastroesophageal Junction
NCT05480384
Recruiting
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
Register for Updates
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
NCT04933903
Recruiting
This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery will be evaluable for the primary endpoint. The primary efficacy outcome measurement will be pathologic response (including Major Pathologic Response (MPR), and Complete Pathologic Response (CPR)). Secon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Non Small Cell Lung Cancer
Register for Updates